No 01 2021

Lithuanian company Celltechna has opened the first and only gene therapy centre in the Baltic States in Vilnius, Lithuania.

NordicRWE is the first Norwegian company to join the AstraZeneca BioVentureHub at the Gothenburg R&D site.

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia.

Victor Ambros and Gary Ruvkun discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation.

The two companies have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.

It is once again time to honor extraordinary scientific discoveries and this will be our 17th Nobel Prize coverage!

Xbrane Biopharma has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo biosimilar candidate Xdivane.